Positive view and increased likely uptake of follow-up testing with analysis of cell-free fetal DNA as alternative to invasive testing among Danish pregnant women

Acta Obstet Gynecol Scand. 2018 May;97(5):577-586. doi: 10.1111/aogs.13297. Epub 2018 Feb 15.

Abstract

Introduction: The aim of this study was to investigate the attitude (view, likely uptake and preferred strategy) towards cell-free fetal DNA (cfDNA) testing among pregnant women before a first-trimester risk assessment for trisomy 21 (unselected women) and after obtaining a high risk.

Material and methods: Unselected and high-risk women attending first-trimester screening (Rigshospitalet, Copenhagen University Hospital) were invited to fill out the questionnaire Antenatal testing for Down syndrome as an online survey.

Results: The survey included 203 unselected and 50 high-risk women (response rates of 74.8% and 84.7%, respectively). Nearly all considered cfDNA testing a positive development in antenatal care, and 97.2% would like it to be offered. Offering cfDNA testing as an alternative to invasive testing would increase the uptake of follow-up testing compared with invasive testing alone (98.8% vs. 90.7%, p < 0.001). Women who would only accept follow up by cfDNA testing were more likely to continue an affected pregnancy (30.0% vs. 3.6%, p < 0.001) or have doubts about termination (50.0% vs. 32.1%, p < 0.001).

Conclusions: Offering cfDNA testing would likely increase the uptake of follow-up testing without a corresponding rise in the termination rate of affected fetuses as some women test for information only. However, both unselected and high-risk women had overwhelmingly positive views underlining attention to avoid routinization.

Keywords: Antenatal testing; cell-free fetal DNA; first trimester screening; high-risk pregnancy; pregnancy; prenatal care; prenatal diagnosis; trisomy 21.

MeSH terms

  • Adolescent
  • Adult
  • Biomarkers / blood
  • Cell-Free Nucleic Acids / blood*
  • DNA / blood*
  • Denmark
  • Down Syndrome / blood
  • Down Syndrome / diagnosis*
  • Down Syndrome / genetics
  • Female
  • Fetus
  • Follow-Up Studies
  • Health Care Surveys
  • Humans
  • Maternal Serum Screening Tests / methods*
  • Patient Acceptance of Health Care*
  • Pregnancy
  • Pregnancy Trimester, First
  • Young Adult

Substances

  • Biomarkers
  • Cell-Free Nucleic Acids
  • DNA